Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04857892 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants
A Phase 1 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT04857892 is a Phase 1 study that has completed, run by ViiV Healthcare. The registered enrollment target is 41 participants.
The verdict
NCT04857892, a Phase 1 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
This is a two part study to compare the relative bioavailability (BA) of 2 fixed dose combinations (FDCs) of GSK3640254/DTG with GSK3640254 and DTG administered together as single agents (Part 1) and to assess the effect of food on the pharmacokinetic (PK) of the selected FDC of GSK3640254/DTG (Part 2).
Interventions
- DRUG DTG
- DRUG GSK3640254
- DRUG GSK3640254/DTG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2021-04-21 |
| Est. Completion | 2021-09-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04857892
The ClinicalTrials.gov registry entry for NCT04857892 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which DTG is the first listed.
NCT04857892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04857892 about?
NCT04857892 is a clinical study titled "A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants". This is a two part study to compare the relative bioavailability (BA) of 2 fixed dose combinations (FDCs) of GSK3640254/DTG with GSK3640254 and DTG administered together as single agents (Part 1) and to assess the effect of food on the pharmacokinetic (PK) of the selected FDC of GSK3640254/DTG (Part...
What is the current status of trial NCT04857892?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2021-04-21. Estimated completion is 2021-09-10.
What interventions are being tested in trial NCT04857892?
The interventions under investigation include: DTG (DRUG), GSK3640254 (DRUG), GSK3640254/DTG (DRUG).
Who is sponsoring clinical trial NCT04857892?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.